主页 > 医学讨论 >
【文摘发布】慢性肾脏病患者贫血起始治疗时每
Clin J Am Soc Nephrol 2: 215-221, 2007
doi: 10.2215/CJN.02590706
There are limited data suggesting that initiation of epoetin alfa at extended dosing intervals of every 2, 3, or 4 wk may be efficacious for treating anemia in patients who have chronic kidney disease and are not on dialysis (CKD-NOD). This open-label, multicenter, single-arm study investigated the efficacy of administration of 20,000 IU of epoetin alfa once every 2 wk as initiation therapy in these patients. Adults with CKD-NOD were eligible when they had hemoglobin (Hb) <11 g/dl, GFR of 10 to 60 ml/min per 1.73 m2, and stable serum creatinine for the past 6 mo. Patients received 20,000 IU of epoetin alfa subcutaneously every 2 wk for up to 27 wk, with dosage adjustments permitted after 4 wk of treatment. The primary efficacy end point was the proportion of patients with Hb response, defined as achievement of the target Hb range of 11 to 12 g/dl for at least two consecutive visits. Sixty-seven patients were enrolled; >88% (59 of 67) of patients achieved an Hb response. Mean Hb increased to the targeted range by week 6 and remained in the range through week 28. Hb increases of 1 and 2 g/dl were observed in 91 and 78% of patients, respectively. Epoetin Alfa was well tolerated; most adverse events were mild or moderate in nature and typical of the CKD patient population. In this study, results demonstrated that epoetin alfa can be initiated safely and effectively at an extended dosing interval of 20,000 IU every 2 wk in patients with CKD-NOD. 本人认领该文，48小时后若未提交译文，请其他战友自由认领。 Epoetin Alfa Once Every 2 Weeks Is Effective for Initiation of Treatment of Anemia of Chronic Kidney Disease
慢性肾脏病患者贫血在起始治疗阶段每两周注射1次重组人红细胞生成素是有效的
Clin J Am Soc Nephrol 2: 215-221, 2007
doi: 10.2215/CJN.02590706
There are limited data suggesting that initiation of epoetin alfa at extended dosing intervals of every 2, 3, or 4 wk may be efficacious for treating anemia in patients who have chronic kidney disease and are not on dialysis (CKD-NOD). This open-label, multicenter, single-arm study investigated the efficacy of administration of 20,000 IU of epoetin alfa once every 2 wk as initiation therapy in these patients.
有限的资料显示：扩大初始的给药间隔时间到2，3，或者4周，对应用重组人红细胞生成素治疗慢性肾脏病未透析患者(CKD-NOD)的贫血是有效的。这个标签公开，多中心，单一目的的试验观察在起始治疗阶段每两周注射1次重组人红细胞生成素20,000 IU 的效果。
Adults with CKD-NOD were eligible when they had hemoglobin (Hb) <11 g/dl, GFR of 10 to 60 ml/min per 1.73 m2, and stable serum creatinine for the past 6 mo. Patients received 20,000 IU of epoetin alfa subcutaneously every 2 wk for up to 27 wk, with dosage adjustments permitted after 4 wk of treatment.
我们的实验对象是血红蛋白<11 g/dl, 肾小球滤过率 在10 到60 ml/min per 1.73 m2，过去6个月血清肌酸酐稳定的成年慢性肾脏病未透析患者。病人每两周接受1次重组人红细胞生成素皮下注射，直到第27周，在用药第4周后允许对用药量进行调整。
The primary efficacy end point was the proportion of patients with Hb response, defined as achievement of the target Hb range of 11 to 12 g/dl for at least two consecutive visits. Sixty-seven patients were enrolled; >88% (59 of 67) of patients achieved an Hb response.
首要效率终点事件是病人出现血红蛋白反应的比例，定义为至少两次连续检测血红蛋白回升到11~12 g/dl。67名病人参与了实验，>88% (67人中的59人)的病人出现了血红蛋白反应。
Mean Hb increased to the targeted range by week 6 and remained in the range through week 28. Hb increases of 1 and 2 g/dl were observed in 91 and 78% of patients, respectively. Epoetin Alfa was well tolerated; most adverse events were mild or moderate in nature and typical of the CKD patient population. In this study, results demonstrated that epoetin alfa can be initiated safely and effectively at an extended dosing interval of 20,000 IU every 2 wk in patients with CKD-NOD.
在第6周，平均血红蛋白上升到了目的范围并保持过28周。91%和78%的病人血红蛋白分别上升了1 g/dl 和2 g/dl。重组人红细胞生成素能很好的耐药；大部分不利事件在自然和典型的慢性肾脏病病人中是温和或者中等的。这个实验的结果证实了：重组人红细胞生成素在慢性肾脏病未透析患者治疗初期，将给药间隔时间扩大到20,000 IU 每两周是安全和有效的。
编译：
慢性肾脏病患者贫血在起始治疗阶段每两周注射1次重组人红细胞生成素是有效的
最新研究显示：扩大初始的给药间隔时间到2，3，或者4周，对应用重组人红细胞生成素治疗慢性肾脏病未透析患者(CKD-NOD)的贫血是有效的。研究者通过观察血红蛋白<11 g/dl, 肾小球滤过率 在10 到60 ml/min per 1.73 m2，过去6个月血清肌酸酐稳定的成年慢性肾脏病未透析患者，在每两周接受1次20,000 IU重组人红细胞生成素皮下注射后直到第27周，病人的血红蛋白反应，发现：67名病人中的59人(>88%)的病人出现了血红蛋白反应；在第6周，平均血红蛋白上升到了目的范围并保持过28周。91%和78%的病人血红蛋白分别上升了1 g/dl 和2 g/dl；并发现重组人红细胞生成素能很好的耐药；大部分不利事件在自然和典型的慢性肾脏病病人中是温和或者中等的。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-15 05:11
医学,生命科学网